2025 American Academy of Neurology Abstract Website

Disclosures for "Five-Year Follow-Up on Natural History of Benign Paroxysmal Torticollis"

Ms. Crandall has nothing to disclose.
Dr. Shin has nothing to disclose.
Dr. Greene has received research support from American Headache Society.
Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Headache Society. The institution of an immediate family member of Dr. Gelfand has received research support from Roche/Genentech. The institution of an immediate family member of Dr. Gelfand has received research support from Vigil Neuroscience. The institution of Dr. Gelfand has received research support from UCSF Resource Allocation Program. The institution of an immediate family member of Dr. Gelfand has received research support from NIH/NINDS. The institution of an immediate family member of Dr. Gelfand has received research support from National MS Society. The institution of Dr. Gelfand has received research support from PCORI. Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Witness with United States Department of Health and Human Services, Vaccine Injury Compensation Program. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Headache Cooperative of the Pacific. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Taiwan Headache Society. An immediate family member of Dr. Gelfand has a non-compensated relationship as a Clinical Trial Steering Committee Member with Roche/Genentech that is relevant to AAN interests or activities.